Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Manipal Group Sets Up Stem Cell Arm in Malaysia (Malaysia)

This article was originally published in PharmAsia News

Executive Summary

Stempeutics Research Pvt. Lab recently disclosed plans to open a subsidiary in Malaysia. The startup will be dubbed Stempeutics Research Malaysia Sdn Bhd. Stempeutic's parent company, the India-based Manipal Education and Medical, will invest between $6 million and $10 million in Stempeutics Malaysia over the next three years. Manipal will also use Stempeutics Malaysia as a jumping off point for research and commercialization in Taiwan and Singapore. Manipal has already invested $7 million in Stempeutics for the company's stem cell research program. Stempeutics is currently researching the prospect of using adult stem cells to treat a number of ailments, including myocardial infarction, multiple sclerosis, limb ischemia and cerebral stroke. Adult stem cells come in two forms. The first are autologous stem cells that are harvested from the patient's own bone marrow. Stempeutics is already conducting several clinical trials into the possible benefits of these stem cells. The company is also waiting for approval from the Indian Council of Medical Research to conduct trials with allogenic stem cells. This type of adult stem cell comes from non-related donor cells. Allogenic stem cells have the benefit of being produced on a large scale. Manipal plans to invest $5 million over the next two years to build a cell manufacturing plant in India. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts